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Abstract
It is not known whether patient age or tumor characteristics such as tumor regression or solar
elastosis influence pathologists’ interpretation of melanocytic skin lesions. We undertook a study
to determine the influence of these factors, and to explore pathologist characteristics associated
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with the direction of diagnosis. To meet our objective, we designed a cross-sectional survey study
of pathologists’ clinical practices and perceptions. Pathologists were recruited from diverse
practices in ten states in the U.S. We enrolled 207 pathologist participants whose practice included
the interpretation of melanocytic skin lesions.
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Our findings indicated that the majority of pathologists (54.6%) were influenced toward a less
severe diagnosis when patients were <30 years of age. Most pathologists were influenced toward a
more severe diagnosis when patients were >70 years of age, or by the presence of tumor regression
or solar elastosis (58.6%, 71.0%, 57.0%, respectively). Generally, pathologists with
dermatopathology board certification and/or a high caseload of melanocytic skin lesions were
more likely to be influenced, while those with more years’ experience interpreting MSL were less
likely to be influenced. Our findings indicate that the interpretation of melanocytic skin lesions is
influenced by patient age, tumor regression, and solar elastosis; such influence is associated with
dermatopathology training and higher caseload, consistent with expertise and an appreciation of
lesion complexity.

INTRODUCTION
Melanoma staging is determined by histologic characteristics that are known to influence
patient outcomes including tumor depth, ulceration, and mitotic rate.(1–3) Of these, tumor
depth was the first prognostic factor to be identified(4) and remains the strongest predictor
of patient outcomes in the absence of tumor extension or metastases.(1)
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While these characteristics form the basis of pathologists’ interpretations of melanocytic
skin lesions, it remains unclear whether additional characteristics of the lesions or patients
also influence interpretations. For example, younger patients, compared to older patients,
have lower melanoma incidence rates(5) and higher melanoma survival rates.(6)
Consequently, younger patient age might influence pathologists toward a less severe
diagnosis, while older patient age may influence toward a more severe diagnosis.
The potential influence of partial tumor regression, uncommon in benign nevi but reported
in up to 58% of melanomas,(7) is more difficult to anticipate. To the extent that tumor
regression obscures depth of invasion, its presence might influence pathologists toward a
more severe diagnosis. On the other hand, melanoma tumor regression may be thought to
represent local host immune response,(8) a potentially favorable process. Studies of
associations between partial tumor regression and metastasis or survival have produced
mixed results, however, with some showing improved outcome(9, 10) and others showing
worse outcome.(11–13)
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Similarly, it is difficult to predict the potential influence of solar elastosis on the direction of
pathologists’ diagnosis. More common in older patients,(14) solar elastosis is a microscopic
marker of chronic sun exposure,(15) and a diagnostic criterion of certain melanoma
subtypes.(16) Thus, its presence might increase suspicion of an atypical melanocytic lesion
or melanoma, swaying pathologists toward a more severe diagnosis. On the other hand,
several studies suggest improved melanoma outcome for patients affected by solar elastosis,
(3, 17, 18) which might influence pathologists toward a less severe diagnosis. Whether
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pathologists consider these factors in their diagnostic interpretations is not known. To
address this gap in knowledge, we sought to determine whether certain contexts (i.e., patient
age, tumor regression, and solar elastosis) influence the severity of pathologists’ diagnoses
when interpreting melanocytic skin lesions. We also assessed pathologist characteristics in
relation to the direction of influence within each context found to be influential.
Although this report does not represent a traditional experimental study, it addresses the
important issue of contexts that influence diagnoses that are central to the interpretation of
much human experimental data.

METHODS
Study Design and Sample Selection

Author Manuscript
Author Manuscript

We conducted a study of pathologists who interpret melanocytic skin lesions (MSL),
including benign nevi, dysplastic nevi, and melanoma. Institutional Review Board approval
for all study procedures was obtained from the of the University of Washington, Fred
Hutchinson Cancer Research Center, Oregon Health & Sciences University, Rhode Island
Hospital, and Dartmouth College. Pathologists were recruited from community practices/
laboratories and academic medical centers in 10 states (CA, CT, HI, IA, KY, LA, NJ, NM,
UT, and WA). We identified potential participants using Internet searches, professional
organizations, and telephone calls to pathology laboratories/practices. Pathologists were
invited to participate via email, postal mail, and telephone from July 2013 through August
2014. Eligibility criteria included completion of residency training and/or fellowship
training, interpretation of MSL within the previous year, expected continuation of
interpreting MSL for the following two years while working in the same state, and verifiable
address of practice location.
Survey Content
After consenting to participate, pathologists completed an online survey that elicited general
demographic and professional information, including training, practice, and perceptions. A
full copy of the survey is available at:http://depts.washington.edu/epidem/faculty/elmorejoann.
Pathologists were asked whether each of certain contexts influenced the direction of their
diagnosis of MSL. The potentially influential contexts included patient-level characteristics
(patient age <30, patient age >70), tumor-level characteristics (areas of extensive tumor
regression, significant solar elastosis).
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Primary Outcome
The primary analytic outcome was the direction of diagnostic influence: influence toward a
less severe diagnosis, no influence on diagnosis, and influence toward a more severe
diagnosis. The vast majority of responses (≥96% within each context) included the noinfluence category and only one direction of influence; consequently, the primary outcome
was dichotomized as follows: (a) “influence toward a less severe diagnosis” versus “no
influence” or (b) “influence toward a more severe diagnosis” versus “no influence,”
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depending on pathologists’ responses for each context. For example, in the context of tumor
regression, 99% of pathologists reported either influence toward a more severe diagnosis or
no influence on diagnosis. Thus, in this context, the primary outcome consisted of
“influence toward a more severe diagnosis” versus “no influence.”
Pathologist Characteristics
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We also explored pathologist characteristics in relation to diagnostic influence. Variables of
interest included pathologist age, gender, residency training, dermatopathology fellowship
training, dermatopathology board certification, MSL caseload (defined as the per month sum
of benign MSL cases and melanoma/melanoma in situ cases), percentage of cases rendered
as borderline or uncertain diagnoses in their final assessment, whether the pathologist
requested second opinions from other pathologists (within our outside their practice) at least
once per month, and whether pathologists requested specialized molecular tests, such as
FISH or CGH.
Statistical Analysis
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Preliminary analyses showed that pathologist age and years of interpreting MSL were highly
correlated (r = 0.85; p < 0.0001), precluding simultaneous inclusion in multivariable models;
thus, we chose to evaluate years of interpreting MSL due to its greater relevance. Due to
almost perfect concordance between dermatopathology fellowship training and board
certification, we chose dermatopathology board certification to represent specialized
knowledge in dermatopathology. Dermatopathology board certification was highly
correlated with higher MSL caseload (r = 0.64; p < 0.0001), and both were considered key
variables. To incorporate both into our analysis, we created a three-level composite variable
representing dermatopathology (DP) expertise: (1) no DP certification and low MSL
caseload (<35 MSL/month), (2) no DP certification and high MSL caseload (≧35 MSL/
month), and (3) DP certification (regardless of caseload). Two variables, the frequency of
using borderline/uncertain diagnosis in final assessments and the frequency of asking for
second opinions, were dichotomized as yes/no because the relationship with the outcome
was not linear.
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Our primary analysis described the percent of pathologists reporting a direction of
diagnostic influence within each of the four contexts. Correlation matrices were used to
assess relationships between pathologist characteristics. The association between
pathologists’ characteristics and the direction of diagnosis was displayed in frequency
distributions and assessed in logistic regression models. We began by exploring bivariate
(unadjusted) models to identify terms for inclusion in multivariable models. Variables
associated with the outcome at p < 0.10 in bivariate models were assessed in multivariable
models. Variables approaching statistical significance (p < 0.06) were retained in the final
multivariable models to allow covariate adjustment. By convention, alpha was set at <0.05
(two-sided tests) for statistical significance in the multivariable models. All statistical
analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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RESULTS
Pathologist Characteristics
Of the 864 potential pathologist participants initially identified, 301 met eligibility criteria
and 207 (69%) completed the online survey. The majority (54%) were age ≥50 years (mean
age 51 years) and male (59%) (Table 1). A minority (39%) were board certified in DP, with
the remainder certified in anatomic pathology, clinical pathology, hematopathology, or
cytopathology. The majority (69%) had interpreted MSL for less than 20 years, and for 63%
the caseload was ≥ 35 MSL per month. Most pathologists (90%) reported ever using the
terms borderline/uncertain in their final pathology report, and most (89%) reported they
requested second opinions of other pathologists at least once per month.
Influence of Context on Direction of Diagnosis
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The percent of pathologists reporting an influence of patient and tumor characteristics on the
direction of their diagnosis within each context is shown in Figure 1. A majority of
pathologists (54.6%) reported that young patient age (<30 years) would influence them
toward a less severe diagnosis, and most (58.5%) reported that older patient age (>70 years)
would influence them toward a more severe diagnosis. The majority of pathologists also
reported they would be influenced toward a more severe diagnosis in the context of
extensive tumor regression (71.0%) or by the presence of significant solar elastosis (57.0%).
The full distribution of pathologist characteristics associated with direction of influence
within each of the four contexts is provided in Appendix A.
Pathologist Characteristics and the Direction of Diagnosis, by Context
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Patient Age <30 Years—Within the context of younger patients (age <30 years), only one
variable, years of interpreting MSL, was associated with self-reported influence toward a
less severe diagnosis in the bivariate analyses, so multivariable analysis was unnecessary.
Compared to pathologists with less experience, those with ≥20 years of experience
interpreting MSL were less likely (OR: 0.36; 95% CI: 0.20, 0.67; p=0.001) to be influenced
toward a less severe diagnosis in the context of younger patient age (Table 2).
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Patient Age >70 Years—Unadjusted analysis showed an association between the
outcome and using the term borderline in a final diagnosis, but this variable lost significance
when adjusted for other pathologist characteristics. Two variables, DP expertise, and years
of interpreting MSL, remained associated with the outcome in adjusted analysis, and were
included in the final multivariable model (Table 2). Compared to those without DP
certification and with low MSL caseload, those with either a high MSL caseload (OR: 2.03;
95% CI: 0.96, 4.29), or DP certification (OR: 2.82; 95% CI: 1.40, 5.69) were at least twice
as likely to be influenced toward a more severe diagnosis when patients were older (global p
= 0.012). Compared to pathologists with less experience, those with ≥20 years experience
interpreting MSL were less likely to be influenced toward a more severe diagnosis (OR:
0.33; 95% CI: 0.17, 0.63; p = <0.001).
Tumor Regression—Unadjusted analysis showed an association between the outcome
and years of interpreting MSL, but this variable lost significance after adjustment for other
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pathologist characteristics. Four variables remained associated with the outcome in adjusted
models, and were retained in the final multivariable model (Table 2): dermatopathology
expertise, years interpreting MSL, using the term borderline in a final diagnosis, and seeking
second opinions. Compared to those without DP certification and with low MSL caseload,
those with either high MSL caseload (OR: 2.87; 95% CI: 1.25, 6.60), or DP certification
(OR: 2.91; 95% CI: 1.29, 6.53) (global p = .0.008) were more likely to be influenced toward
a more severe diagnosis. Pathologists who ever used the terms borderline/uncertain when
interpreting MSL were also more likely to be influenced toward a more severe diagnosis by
tumor regression (OR: 4.73; 95% CI: 1.66, 13.53; p = 0.004), as were those who requested
second opinions at least once per month (OR: 3.04; 95% CI: 1.12, 8.26; p = 0.029).
Although the association was marginally significant, those with ≥20 years of experience
interpreting MSL, compared to those with fewer years, were half as likely to be influenced
toward a more severe diagnosis (OR: 0.49; 95% CI: 0.24, 1.02; p = 0.057).
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Solar Elastosis—Two variables: years interpreting MSL, and ordering FISH/CGH or
other molecular tests, were associated with the outcome in the unadjusted analysis, but were
not statistically significant after adjustment for other pathologist characteristics. Three
variables remained associated after adjustment, and were included in the final multivariable
model: DP expertise, using borderline/uncertain diagnosis, and requesting second opinions
(Table 2). Compared to non-DP certified, low-MSL volume pathologists, those with either
high MSL volume (OR: 2.06; 95% CI: 0.98, 4.35), or DP certification (OR: 4.07; 95% CI:
1.98, 8.38) were more likely to be influenced toward a more severe diagnosis (global p =
<0.001). Pathologists who ever used the terms borderline/uncertain when interpreting MSL
were also more likely to be influenced toward a more severe diagnosis (OR: 2.94; 95% CI:
1.03, 8.37; p = 0.044), as were those who requested second opinions at least once per month
(OR: 5.45; 95% CI: 1.92, 15.43; p = 0.001).

DISCUSSION
We identified four influential contexts that impact the severity of diagnosis: younger patient
age, older patient age, tumor regression, and solar elastosis. Only one context, younger
patient age, influenced pathologists toward a less severe diagnosis. The three remaining
contexts influenced pathologists toward a more severe diagnosis.
Our results concerning patient age are compatible with studies showing a more favorable
prognosis in younger patients than in older patients.(6) In addition, melanoma is less
common in younger than in older individuals(5); thus, the prior probability of disease and
the predictive value of a diagnosis of melanoma are greater in older populations.
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A majority of pathologists in our study reported they were influenced toward a more severe
diagnosis by melanoma with extensive tumor regression. Such influence may reflect
longstanding concerns that tumors with regression have invaded beyond their measurable
depth.(19) Consistent with this concern, some studies have shown a worse outcome for
patients with regressed tumors (reviewed in Piepkorn & Barnhill, 2014).(20) Other studies,
however, have indicated that tumor regression predicts better outcome, while still others
have shown no association (reviewed in Piepkorn & Barnhill, 2014).(20) A recent meta-
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analysis of 14 studies,(10) published after our study was underway, noted a strong, inverse
association between tumor regression and lymph node metastasis, implying more favorable
survival, but heterogeneity was substantial among the analyzed studies.(10) It should also be
noted that nearly half of melanomas disseminate without first invading the regional lymph
nodes.(21, 22) Thus, the prognostic role of tumor regression, which has implications for
diagnostic interpretation, and possibly for staging, remains unclear.
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The majority of pathologists in our study were also swayed toward a more severe diagnosis
by the presence of significant solar elastosis, a biological marker of chronic sun exposure.
(15) This finding seems inconsistent with the relatively slow radial growth rate of lentigo
maligna melanoma, the histologic subtype for which solar elastosis is a diagnostic criterion,
(16) and with past studies showing a favorable influence of solar elastosis on prognosis.(3,
17, 18) However, solar elastosis is an indicator of long term sun exposure, which is a known
risk factor for lentigo maligna melanoma,(23) and is infrequently found with benign nevi, so
its presence in a melanocytic skin lesion may increase suspicion of malignancy.
We also explored pathologist characteristics associated with influence on the direction of
diagnosis. Pathologists with more years of MSL interpretation, who also were necessarily
older, were less likely to be influenced toward a less severe diagnosis in the context of
younger patient age. They were also less likely to be influenced toward a more severe
diagnosis in the context of older patient age and tumor regression. While speculative, these
findings may reflect complacency or over-confidence in those with long-term experience
interpreting MSL.
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Our findings were similar for pathologists who had high MSL caseloads, but lacked DP
certification, and for those with DP board certification. Both groups were more likely to be
influenced toward a more severe diagnosis in the contexts of older age, tumor regression,
and solar elastosis. Those who designated tumors as borderline/uncertain in their final
reports, and who requested a second opinion at least monthly were also more likely to be
influenced toward a more severe diagnosis in contexts of tumor regression or solar elastosis.
These pathologist characteristics are consistent with a higher level of sophistication and
appreciation of lesion complexity, although requesting second opinions may also reflect
laboratory policies.
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Our study relies on self-reported data describing the influence of direction of diagnosis, but
there is no reason to assume pathologists would incorrectly report their usual practice. We
also did not compare the diagnostic accuracy of pathologists with more years of MSL
interpretation to that of pathologists with specialized DP expertise. However, a recent
analysis, based on the same group of pathologists, showed a significantly lower percentage
of malpractice suits among those with DP fellowship training or board certification,(24)
suggesting greater accuracy among those with specialized training. Our sample of
pathologists, although arising from diverse settings and geographic areas, may not
generalize to the population of US pathologists. However, we found no differences between
pathologists who agreed to enroll in our study and those who did not. We also cannot be
certain that the direction of influence reported by pathologists reflects their actual practice.
Strengths of our study include the diversity of the study sample, which represents
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pathologists in ten states, a 69% response rate among eligible participants, exceeding the
national standard for physician surveys,(25) the detailed information gathered on the survey,
and the quality of the analysis.
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Our findings underscore complexity inherent in the subjective process of histological
diagnosis of melanocytic skin lesions, revealing possible explanations for diagnostic
discordance rates for melanoma and illustrating the potential for misclassification errors,
with potentially substantial public health impacts, when identifying patient populations
diagnosed with this maligancy. Future research may be helpful to assess the potential role of
additional pathologist characteristics and other factors not evaluated here, as well as to
determine whether the factors identified in this study may result in biases associated with the
interpretation of more recent, “objective” diagnostic technology, including
immunohistochemical markers, fluorescence in situ hybridization, comparative genomic
hybridization, and gene expression profiling.
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Figure 1.

MPATH - Patient and Tumor Characteristics and the Direction of a Diagnosis (n=207)
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Characteristics of participating pathologists (n=207)
Pathologist characteristic

number (%)

Age (yrs.)
< 40

36 (17.4)

40–49

59 (28.5)

50–59

71 (34.3)

≥ 60

41 (19.8)

Mean age (SD)

51 (10.2)

Sex
Male

123 (59.4)

Female

84 (40.6)

Author Manuscript

Board certification
Dermatopathology (DP) ***

81 (39.1)

Other

126 (60.9)

Melanocytic skin lesion caseload per month**
Low

76 (36.7)

High

131 (63.3)

Composite variable: DP certified and melanocytic skin lesion caseload**
Not DP certified, low caseload

72 (34.8)

Not DP certified, high caseload

54 (26.1)

DP certified

81 (39.1)

Years interpreting melanocytic skin lesions

Author Manuscript

<20

143 (69.1)

≥20

64 (30.9)

Ever interpret melanocytic skin lesions as borderline or uncertain
No

21 (10.1)

Yes

186 (89.8)

Asks for second opinion at least once per month
No

22 (10.6)

Yes

185 (89.4)

Requests FISH/CGH or other molecular analysis
No

128 (61.8)

Yes

79 (38.2)

Author Manuscript

*

sum of number of melanomas + benign melanocytic skin lesions interpreted per month

**

average number of melanocytic skin lesions interpreted/month: low caseload <35/month; high caseload ≥35/month.

***

pathologists in this category have single or multiple certifications/fellowship training including dermatopathology
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.

- n/a-

3.04 (1.12,8.26)

- ref -

5.45 (1.92,15.43)

- ref -

2.94 (1.03,8.37)

- ref -

n/a

4.07 (1.98,8.38)

2.06 (0.98,4.35)

- ref -

Adjusted OR (95% CI)

More Severe (vs. No
Influence)

Solar elastosis

Lab Invest. Author manuscript; available in PMC 2017 May 28.

Average number of melanocytic skin lesions interpreted/month: low caseload <35/month; high caseload ≥35/month

**

OR adjusted for variables with results shown in the same column. Variables denoted by n/a (not applicable), were not included in the adjusted model. Variables associated with the outcome at p < 0.05 are
shown in bold.

*

Yes

No

n/a

4.73 (1.66 -13.53)

Asks for second opinions

- ref -

0.49 (0.24,1.02)

- ref -

Yes

n/a

0.33 (0.17,0.63)

- ref -

2.91 (1.29,6.53)

2.87 (1.25,6.60)

- ref -

Adjusted OR (95% CI)

More Severe (vs. No Influence)

Tumor regression

No

n/a

0.36 (0.20,0.67)

≥ 20

Interprets melanocytic skin lesions as borderline or uncertain

- ref -

< 20

Years interpreting melanocytic skin lesions

2.82 (1.40,5.69)

DP certified

- ref 2.03 (0.96,4.29)

--

n/a

Adjusted OR (95% CI)

More Severe (vs. No
Influence)

Less Severe (vs. No
Influence)
Adjusted OR (95% CI)

Patient age > 70

Patient age < 30

Not DP certified, high caseload

Not DP certified, low caseload

DP certification and melanocytic skin lesion caseload**

Pathologist characteristic

Direction of influence on diagnosis

Context

tumor characteristics* (n=207)

Odds ratios (OR) and 95% confidence intervals (CI) for the association between pathologist characteristics and direction of diagnosis, by patient age and
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